Konakion Mm Paediatric (Phytomenadione)

Konakion Mm Paediatric provides vitamin K supplementation for conditions affecting the coagulation cascade.

• Vitamin K deficiency bleeding in newborns: prevents hemorrhage during the first days of life.
• Warfarin anticoagulation reversal: restores normal clotting in patients receiving warfarin therapy.
• Prevention of postoperative bleeding in pediatric surgery: ensures adequate coagulation after surgical procedures.

• Phytomenadione acts as a cofactor for the hepatic enzyme gamma‑carboxylase, enabling the gamma‑carboxylation of glutamate residues on clotting factors II, VII, IX and X. This modification is essential for the factors to bind calcium and participate in the coagulation cascade, thereby restoring normal clotting function.

Konakion Mm Paediatric may be associated with several adverse reactions.

Common Side Effects

• Injection site pain: mild discomfort at the site of administration.
• Redness or erythema: localized skin irritation.
• Transient fever: low‑grade temperature rise shortly after injection.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe bleeding: paradoxical hemorrhage despite vitamin K administration.
• Thrombosis or hypotension: abnormal clot formation or sudden drop in blood pressure.

Use of Konakion Mm Paediatric requires careful clinical consideration.

• Use only under medical supervision: dosage determined by the prescriber.
• Check for known hypersensitivity: avoid in patients allergic to phytomenadione or excipients.
• Monitor coagulation parameters: assess PT/INR after administration.
• Avoid in severe liver disease: impaired metabolism may affect efficacy.
• Do not mix with incompatible IV solutions: ensure compatibility before co‑administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Phytomenadione can interact with several medications affecting coagulation.

Major Interactions (Avoid)

• Warfarin: concurrent use may blunt reversal effect.
• Broad‑spectrum antibiotics (e.g., cephalosporins): may reduce vitamin K synthesis.
• Other vitamin K preparations: risk of overdose.

Moderate Interactions (Monitor Closely)

• Heparin: additive anticoagulant effect may increase bleeding risk.
• Oral contraceptives: potential alteration of clotting balance.
• Blood products containing vitamin K antagonists: monitor coagulation closely.